AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04341805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PrevOmega
Description: The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
Study NCT04341805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline
Description: The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
Study NCT02324504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C3 Wave ECG-based PICC Tip Confirmation System
Description: The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
Study NCT03588533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks
Study NCT03588533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: - Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
Study NCT00216619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
Study NCT03588533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: - Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
Study NCT03244527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA supplement
Description: Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
Study NCT03244527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BCAA supplement
Description: Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
Study NCT03244527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
Study NCT03244527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
Study NCT05630274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT03121599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic (18F-FLT PET/CT)
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
Study NCT05630274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally
Study NCT05630274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04824404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT-Buprenorphine + Recovery Coach
Description: This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
Study NCT02216123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
Study NCT02216123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine Placebo
Description: Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
Study NCT02216123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base).
Study NCT02216123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
Study NCT02216123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Placebo
Description: Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate feedback through electronic reminder messages
Description: After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immediate feedback through electronic reminder messages
Description: After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted interventions in each ICU to reduce discomforts
Description: These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures.
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Targeted interventions in each ICU to reduce discomforts
Description: These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures.
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 months follow-up to assess the prevalence of PTSD symptoms
Description: Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 year follow-up to assess psychiatric morbidity
Description: Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1 year follow-up to assess psychiatric morbidity
Description: Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
Study NCT03991611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 year follow-up to assess psychiatric morbidity
Description: Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
Study NCT05560672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord blood mononuclear cells
Description: Intravenous infusion of cord blood mononuclear cells
Study NCT02239679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: 20% ALA applied to face for one hour prior to 10 J/cm2 blue light
Study NCT02239679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Solution Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
Study NCT02239679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 blue light delivered at 10 mW/cm2
Study NCT02604147 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory pressure-threshold muscle training device.
Description: The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
Study NCT02604147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nspiratory pressure-threshold muscle training device.
Description: The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
Study NCT03022734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
Study NCT03022734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
Study NCT01468025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Theramine and Active Naproxen
Description: Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
Study NCT01468025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theramine and naproxen-like placebo
Description: Theramine, a medical food, co-administered with naproxen-like placebo
Study NCT01468025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen and Theramine-like placebo
Description: naproxen co-administered with Theramine-like placebo.
Study NCT02409823 — intervention group
Intervention type: DRUG
Intervention: Atypical Antipsychotics
Description: any atypical antipsychotic
Study NCT00957671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
Study NCT01509040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours.
Study NCT01509040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours.
Study NCT01509040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Volume Hemofiltration
Description: Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required.
Study NCT01509040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Volume Hemofiltration
Description: Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required.
Study NCT04388514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Ozone procedure
Description: The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
Study NCT02158793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniomaxillofacial allotransplantation
Description: Transplantation of donor face
Study NCT03999697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
Description: The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
Study NCT01225705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Patients will be randomized 1:1 to either the experimental or the active control arm
Study NCT01225705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/ritonavir
Description: Patients will be randomized 1:1 to either the experimental or the active control arm
Study NCT00850798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Description: Intensive glycemic control
Study NCT00850798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative glycemic control
Description: OADs and insulin
Study NCT02286427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane
Study NCT02286427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Membrane
Study NCT02896218 — intervention group
Intervention type: OTHER
Intervention: Pharmacists consultation
Description: Pharmacists consultation of vancomycin individualized dosing strategy
Study NCT02744898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Study NCT02744898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m2
Study NCT02574949 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation: 15 FPS Cine 15 PPS
Description: Radiation 15 FPS Cine 15 PPS
Study NCT02574949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: 7.5 low Frame rate
Description: Radiation: Frame rate 7.5 FPS, Cine 15 PPS
Study NCT02574949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Cine
Description: Radiation: Frame rate 7.5 FPS, Cine 10 PPS
Study NCT02113150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: renal function
Study NCT02113150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: renal function
Study NCT01504919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
Study NCT01504919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
Study NCT01504919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Sessions
Description: 9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
Study NCT01504919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: 6-week supply of nicotine patches given to participants ready to quit smoking.